AMLX

Dopo l'orario di chiusura: 16.89 -0.03 -0.18%

Amylyx Pharmaceuticals Inc (AMLX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Amylyx Pharmaceuticals Inc

Healthcare (1110)

617-682-0917

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Prossima data di guadagno

Ultimi documenti SEC

AMLX's Discussions on Twitter

Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AMLX Amylyx Pharmaceuticals Inc	16.92	1.81B	-665.00K	-144.74M	-123.48M	-1.5527
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-03	Iniziato	Stifel	Buy
2025-07-10	Ripresa	Goldman	Buy
2025-06-24	Iniziato	Guggenheim	Buy
2025-06-17	Iniziato	Citigroup	Buy
2025-05-30	Iniziato	TD Cowen	Buy
2025-04-07	Aggiornamento	Mizuho	Neutral → Outperform
2024-11-18	Aggiornamento	Robert W. Baird	Neutral → Outperform
2024-10-23	Aggiornamento	BofA Securities	Neutral → Buy
2024-03-18	Downgrade	Mizuho	Buy → Neutral
2024-03-11	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-11	Downgrade	Robert W. Baird	Outperform → Neutral
2024-03-08	Downgrade	Evercore ISI	Outperform → In-line
2024-03-08	Downgrade	Goldman	Buy → Neutral
2024-01-03	Iniziato	Robert W. Baird	Outperform
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-07-24	Aggiornamento	Goldman	Neutral → Buy
2023-03-31	Iniziato	Mizuho	Buy
2023-01-05	Iniziato	BofA Securities	Buy
2022-05-25	Iniziato	Citigroup	Buy
2022-04-01	Downgrade	Goldman	Buy → Neutral

Mostra tutto

Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie

Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie

Bull Run: What is Amylyx Pharmaceuticals Incs book value per share2026 Dividend Review & Daily Profit Maximizing Tips - baoquankhu1.vn

Amylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and history - Yahoo Finance Singapore

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz

Layoff Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Patterns & AI Powered Trade Plan Recommendations - baoquankhu1.vn

AMLX SEC FilingsAmylyx Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace

Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential - TipRanks

A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone - Sahm

Amylyx Pharmaceuticals Inc (AMLX) Shares Up 6.66% on Apr 6 - GuruFocus

Amylyx Pharmaceuticals Shares Rise 6.9% on Positive News - National Today

Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 6.9%What's Next? - MarketBeat

Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis

Amylyx Pharmaceuticals Inc (AMLX) Shares Up 3.52% on Apr 2 - gurufocus.com

AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill

The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following LUCIDITY Trial Enrollment Milestone Completion - Sahm

Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9%Still a Buy? - MarketBeat

Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment - Insider Monkey

Buyback Watch: Is Amylyx Pharmaceuticals Inc stock a smart retirement pick2026 Trade Ideas & Smart Allocation Stock Tips - baoquankhu1.vn

A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment - simplywall.st

Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance

Vanguard realigns holdings; AMLX ownership reported at 0% (Vanguard) - Stock Titan

Market Recap: Is Amylyx Pharmaceuticals Inc benefiting from interest rate changesEarnings Recap Summary & Fast Gain Swing Alerts - baoquankhu1.vn

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

HC Wainwright Reaffirms Buy Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat

H.C. Wainwright reiterates Amylyx stock rating on trial progress By Investing.com - za.investing.com

H.C. Wainwright reiterates Amylyx stock rating on trial progress - Investing.com

Amylyx Pharmaceuticals Advances Novel Therapies for Rare Diseases: Avexitide, AMX0035, and AMX0114 Show Promise in Clinical Trials for PBH, Wolfram Syndrome, and ALS - Minichart

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace

Amylyx Highlights Pipeline Progress in Updated Corporate Presentation - TipRanks

Amylyx Pharmaceuticals completes enrollment in Phase 3 LUCIDITY trial for PBH - Traders Union

Amylyx updates presentation: LUCIDITY and LUMINA enrollment complete; LUCIDITY topline due Q3 2026 - TradingView

Amylyx (NASDAQ: AMLX) details avexitide Phase 3 timing and cash runway into 2028 - Stock Titan

Amylyx Pharmaceuticals Q4 2025 earnings preview - MSN

Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart

Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat

Amylyx Pharmaceuticals Inc (AMLX) Shares Gap Down to $13.78 on M - GuruFocus

Maven Securities LTD Makes New $951,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat

Fund Flows: Is Amylyx Pharmaceuticals Inc stock a smart retirement pickPortfolio Gains Report & Weekly Sector Rotation Insights - baoquankhu1.vn

Amylyx shares slip despite Q4 beat as investors focus on trial timeline - MSN

Amylyx Pharmaceuticals expands team to address urgent healthcare challenges - Traders Union

How Investors May Respond To Amylyx Pharmaceuticals (AMLX) Narrowed 2025 Losses And Expanded Shelf Capacity - simplywall.st

Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program - TipRanks

First Light Asset Management LLC Purchases Shares of 3,355,882 Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Boxer Capital Management LLC - MarketBeat

Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AMLX